Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
Status:
Terminated
Trial end date:
2020-06-18
Target enrollment:
Participant gender:
Summary
This research is being done to test if it is safe to give nivolumab with targeted
immunotherapy drugs for recurrent glioblastoma (GBM), a type of brain tumor. The study
doctors believe that giving immunotherapy drugs that match the biomarkers in a tumor will
help the immune system fight the tumor. Tumor tissue collected during surgery will be tested
for certain biomarkers to determine which immunotherapy might best target the tumor.
The combination immunotherapy arms include:
Arm A: Nivolumab + anti-GITR Arm B: Nivolumab + IDO1 inhibitor Arm C: Nivolumab + Ipilimumab
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins